Rituximab and chemotherapy in diffuse large B-cell lymphoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 719-726

  Sonet, Anne ^a   Bosly, André ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

CD20; Diffuse large B cell lymphoma; Prognostic factor; Rituximab

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; OXALIPLATIN; PREDNISOLONE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; EVENT FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; AGE; AGED; MIDDLE AGED; REVIEW; RISK FACTOR;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RISK FACTORS; VINCRISTINE;

EID: 68849094469     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.30     Document Type: Article

References (55)

1. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab in non-Hodgkin's lymphoma. Oncogene 24, 2121-2143 (2005).
2. + cytotoxic T cells. Leukemia 15, 1619-1626 (2001).
3. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am. Soc. Hematol. Educ. Program 2007, 233-242 (2007).
4. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997).
5. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
6. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20) monoclonal antibody as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97(1), 101-106 (2001).
7. Ghielmini M, Schmitz SF, Coliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103(12), 4416-4423 (2004).
8. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23(6), 1088-1095 (2005).
9. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17(1), 268-276 (1999).
10. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22(23), 4711-4716 (2004).
11. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417-1423 (2005).
12. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005).
13. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 25(15), 1986-1992 (2007).
14. Salles GA, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELA-GOELAMS FL 2000 study with a 5-year follow-up. Blood 110(11-Part 1), 243a, 792 (2007).
15. Turturro F. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Exp. Rev. Anticancer Ther. 7(7), 959-968 (2007).
16. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 92(6), 1927-1932 (1998).
17. Vose JM, Link BK, Grossbard ML et al. Long-term update of a Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma 46, 1569-1573 (2005).
18. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328(14), 1002-1006 (1993).
19. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
20. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 23(18), 4117-4126 (2005).
21. Coiffier B, Feugier P, Mounier N et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J. Clin. Oncol. 25(18S Part I), 443S (2007) (Abstract).
22. Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104(5), 634-641 (2004).
23. + B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 9(2), 105-116 (2008).
24. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24(19), 3121-3127 (2006).
25. Morrison VA, Weller EA, Habermann TM et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an intergroup E4494/C9793 update. Blood (ASH Annual Meeting Abstracts) 110(11-Part 1), 8011 (2007).
26. Sonneveld P, van Putten W, Biesma D et al. Phase III trial of 2 weekly CHOP with rituximab for aggressive B cell non-Hodgkin's lymphoma in elderly patients. Blood (ASH Annual Meeting Abstracts) 10, 210 (2006).
27. Pfreundschuch M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial TMInT) Group. Lancet Oncol. 7(5), 379-391 (2006).
28. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23(22), 5027-5033 (2005).
29. Trneny M, Belada D, Vasova I et al. Rituximab combination with acyclin based chemotherapy significantly improved the outcome of young patients with diffuse large B cell lymphoma in low as well as in high risk subgroups. Blood (ASHAnnual Meeting Abstracts) 10, 2444 (2005).
30. Wilson WH, Grossbard ML, Pittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99(8), 2685-2693 (2002).
31. Wilson WH, Gutierrez M, O'Connor P et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin. Oncol. 29 (1 Suppl. 2), 41-47 (2002).
32. Glass B, Kloess M, Bentz M et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107(8), 3058-3064 (2006).
33. Zelenetz AD, Hamblin P, Kewelramani T et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol. 14 (Suppl. 1), i5-i10 (2003).
34. Kewelramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103(10), 3684-3688 (2004).
35. Philip T, Chauvin F, Armitage J et al. Parma international protocol: pilot study of DHAP followed by involve-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77(7), 1587-1592 (1991).
36. Mey UJ, Olivieri A, Orlopp KS et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk. Lymphoma 47(12), 2558-2566 (2006).
37. El Gnaoui T, Dupuis J, Belhadj K et al. Rituximab gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphomas not candidates for high-dose therapy. Ann. Oncol. 18, 1363-1368 (2007).
38. Morschhauser F, Illidge T, Huglo D et al. Efficacy and safety of Yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110, 54-58 (2007).
39. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B et al. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk. Lymphoma 47, 1830-1840 (2006).
40. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11), 4207-4213 (2006).
41. Hermine O, Haioun C, Lepage E et al. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87, 265-272 (1996).
42. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101(11), 4279-4284 (2003).
43. Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal centers biomarkers. J. Clin. Oncol. 26(16), 2717-2724 (2008).
44. Liu YY, Leboeuf C, Shi JY et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 110(1), 339-344 (2007).
45. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
46. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunochemistry using a tissue microarray. Blood 103, 275-282 (2004).
47. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109, 4930-4935 (2007).
48. Sehn LH, Berry B, Chhanabbai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5), 1857-1861 (2007).
49. 18Ffluoro-2-deoxy-[s D s]-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106, 1376-1381 (2005).
50. 18fluoro-deoxy-glucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 92, 778-783 (2007).
51. Delarue R, Mounier N, Haioun C et al. Safety of prophylactic use of darbepoetin α in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B randomized GELA study. Blood (ASH Annual Meeting Abstracts) 108(11), 689a (2006).
52. Micallef IN, Kahl BS, Maurer MJ et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107(12), 2826-2832 (2006).
53. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk. Lymphoma 47(6), 998-1005 (2006).
54. Rice RD, Moskowitz CH, Kewelramani T et al. Rituximab maintenance following high dose therapy and autologous stem cell rescue after RICE cytoreduction improves event free and overall survival. Blood (ASH Annual Meeting Abstracts) 110(11), 1280 (2007).
55. Gisselbrecht C, Schmitz N, Mounier N et al. R-ICE versus R-DHAP in relspsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood (ASH Annual Meeting Abstracts) 110(11), 517 (2007).